CL2021002056A1 - Inhibidores de arginasa y métodos de uso de estos. - Google Patents

Inhibidores de arginasa y métodos de uso de estos.

Info

Publication number
CL2021002056A1
CL2021002056A1 CL2021002056A CL2021002056A CL2021002056A1 CL 2021002056 A1 CL2021002056 A1 CL 2021002056A1 CL 2021002056 A CL2021002056 A CL 2021002056A CL 2021002056 A CL2021002056 A CL 2021002056A CL 2021002056 A1 CL2021002056 A1 CL 2021002056A1
Authority
CL
Chile
Prior art keywords
methods
compounds
formula
arginase inhibitors
arginase
Prior art date
Application number
CL2021002056A
Other languages
English (en)
Spanish (es)
Inventor
Maurice Raymond Verschoyle Finlay
Scott Nathan Mlynarski
Tyler Grebe
Sameer Kawatkar
Iain Simpson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2021002056A1 publication Critical patent/CL2021002056A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2021002056A 2019-02-08 2021-08-04 Inhibidores de arginasa y métodos de uso de estos. CL2021002056A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08

Publications (1)

Publication Number Publication Date
CL2021002056A1 true CL2021002056A1 (es) 2022-03-04

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002056A CL2021002056A1 (es) 2019-02-08 2021-08-04 Inhibidores de arginasa y métodos de uso de estos.

Country Status (33)

Country Link
US (2) US12435097B2 (https=)
EP (1) EP3921033B1 (https=)
JP (1) JP7526734B2 (https=)
KR (1) KR102759971B1 (https=)
CN (1) CN113395996B (https=)
AU (1) AU2020218651B2 (https=)
BR (1) BR112021015581A2 (https=)
CA (1) CA3127755A1 (https=)
CL (1) CL2021002056A1 (https=)
CO (1) CO2021011039A2 (https=)
CR (1) CR20210463A (https=)
DK (1) DK3921033T3 (https=)
DO (2) DOP2021000166A (https=)
EA (1) EA202192114A1 (https=)
ES (1) ES2960034T3 (https=)
FI (1) FI3921033T3 (https=)
HR (1) HRP20231092T1 (https=)
HU (1) HUE062968T2 (https=)
IL (1) IL285108B2 (https=)
LT (1) LT3921033T (https=)
MA (1) MA56324B1 (https=)
MX (1) MX2021009499A (https=)
MY (1) MY206577A (https=)
PE (1) PE20220280A1 (https=)
PH (1) PH12021551902A1 (https=)
PL (1) PL3921033T3 (https=)
PT (1) PT3921033T (https=)
RS (1) RS64781B1 (https=)
SG (1) SG11202108503PA (https=)
SI (1) SI3921033T1 (https=)
SM (1) SMT202300337T1 (https=)
WO (1) WO2020161675A1 (https=)
ZA (1) ZA202105833B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
LT2389352T (lt) 2009-01-26 2019-06-10 The Trustees Of The University Of Pennsylvania Arginazės inhibitoriai ir naudojimo būdai
SG10201503168VA (en) * 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
WO2013059437A1 (en) 2011-10-19 2013-04-25 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
RU2018138195A (ru) * 2012-12-17 2018-12-18 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US10143699B2 (en) * 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2017175185A1 (en) 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
CN108794517B (zh) 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
CN117186134A (zh) * 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
CN111770756B (zh) 2018-04-27 2023-03-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) * 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Also Published As

Publication number Publication date
DOP2024000181A (es) 2024-10-15
BR112021015581A2 (pt) 2021-10-05
CN113395996A (zh) 2021-09-14
HUE062968T2 (hu) 2023-12-28
EP3921033A1 (en) 2021-12-15
CO2021011039A2 (es) 2021-09-09
SMT202300337T1 (it) 2023-11-13
JP7526734B2 (ja) 2024-08-01
PT3921033T (pt) 2023-10-11
US20250282800A1 (en) 2025-09-11
IL285108A (en) 2021-09-30
KR102759971B1 (ko) 2025-01-23
ZA202105833B (en) 2025-03-26
MA56324B1 (fr) 2023-10-31
IL285108B1 (en) 2024-06-01
FI3921033T3 (fi) 2023-09-15
PL3921033T3 (pl) 2024-01-15
DK3921033T3 (da) 2023-10-16
DOP2021000166A (es) 2021-09-30
MX2021009499A (es) 2021-09-08
JP2022521474A (ja) 2022-04-08
PE20220280A1 (es) 2022-02-25
SI3921033T1 (sl) 2023-11-30
IL285108B2 (en) 2024-10-01
CR20210463A (es) 2021-10-15
SG11202108503PA (en) 2021-09-29
WO2020161675A1 (en) 2020-08-13
ES2960034T3 (es) 2024-02-29
RS64781B1 (sr) 2023-11-30
KR20210126044A (ko) 2021-10-19
PH12021551902A1 (en) 2022-08-01
US12435097B2 (en) 2025-10-07
AU2020218651B2 (en) 2023-01-12
US20220106335A1 (en) 2022-04-07
LT3921033T (lt) 2023-09-25
CA3127755A1 (en) 2020-08-13
EA202192114A1 (ru) 2021-12-01
EP3921033B1 (en) 2023-07-26
AU2020218651A1 (en) 2021-09-30
CN113395996B (zh) 2024-05-28
MY206577A (en) 2024-12-24
HRP20231092T1 (hr) 2023-12-22

Similar Documents

Publication Publication Date Title
CL2020002096A1 (es) Inhibidores de arginasa y sus métodos de uso.
DOP2024000181A (es) Inhibidores de arginasa y métodos de uso de estos
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
PE20241127A1 (es) Compuestos triciclicos como inhibidores de kras
PE20230238A1 (es) Inhibidores de kras g12c
CO6251294A2 (es) Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer
CY1107221T1 (el) Παραγωγα τριαζολιου ως ανταγωνιστες υποδοχεα ταχυκινινης
PE20220768A1 (es) Inhibidores de molecula pequena de quinasa inductora de nf-kb
PE20210404A1 (es) Derivados de pirrolo [1,2-b] piridazina
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
MX2024011538A (es) Inhibidores de molecula peque?a de miembros de la familia de dominio transcripcional mejorado asociado (tea).
ECSP22054240A (es) Compuesto y composici?n como inhibidor de quinasa del receptor pdgf
ECSP22027287A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
DOP2022000075A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
EA202091886A1 (ru) Ингибиторы аргиназы и способы их применения
TH2001004359A (th) ตัวยับยั้งอาร์จิเนสและวิธีการใช้สิ่งดังกล่าว
MX2022000904A (es) Inhibidores de arginasa y métodos de uso de estos.
AR114394A1 (es) Inhibidores de arginasa y sus métodos de uso
NZ767738B2 (en) Arginase inhibitors and methods of use thereof